Shares of Agilent Technologies Inc (NYSE:A) ended Friday session in red amid volatile trading. The shares closed down -0.66 points or -1.40% at $46.37 with 2.22 million shares getting traded. Post opening the session at $46.77, the shares hit an intraday low of $46.21 and an intraday high of $46.87 and the price vacillated in this range throughout the day. The company has a market cap of $14.83 billion and the numbers of outstanding shares have been calculated to be 324.38 million shares.
Agilent Technologies Inc (A) recently released Cartagenia Bench Lab 5.0, a major new version of its lab software with new capabilities for somatic variant classification and reporting.
Cartagenia Bench Lab is designed to assist laboratories involved in clinical genetics and molecular pathology efficiently interpret and report on genomic variants. The clinical-grade software platform – registered as an exempt Class I Medical Device in the U.S. – has become the platform of choice for high-throughput diagnostic labs to assist them validate and automate their variant assessment and reporting pipelines.
The software facilitates clinical geneticists and molecular pathologists to combine single nucleotide polymorphisms; small insertions and deletions (INDELs); and copy number variations into one seamless analysis. Variant curation tools allow them to review variants, collaboratively build evidence and securely share it with their peers and data-sharing communities.
Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) ended Friday session in green amid volatile trading. The shares closed up +0.04 points or 2.50% at $1.64 with 2.37 million shares getting traded. Post opening the session at $1.61, the shares hit an intraday low of $1.57 and an intraday high of $1.64 and the price vacillated in this range throughout the day. The company has a market cap of $411.49 million and the numbers of outstanding shares have been calculated to be 243.31 million shares.
Arena Pharmaceuticals, Inc. (ARNA) recently stated financial results for the third quarter ended September 30, 2016.
Third Quarter 2016 Financial Results
Revenues totaled $19.2 million, counting $3.3 million in net product sales of BELVIQ and $11.0 million in milestone payments earned from Eisai for BELVIQ
Research and development expenses totaled $17.5 million
General and administrative expenses totaled $8.6 million
Restructuring charges totaled $0.2 million
Net loss attributable to stockholders of Arena was $12.4 million or $0.05 per share
At September 30, 2016, cash and cash equivalents totaled $101.6 million and about 243 million shares of Arena common stock were outstanding